Skip to main content
. Author manuscript; available in PMC: 2016 Jan 14.
Published in final edited form as: J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):57–64. doi: 10.1097/QAI.0000000000000821

Table 2.

Baseline characteristics by ARRA1 biomarker availability

With biomarker
(n=224)
Without biomarker
(n=225)
p-value*
Age (years) 49.7(46.9–54.4) 48.4(44.9–53.2) 0.002
Race (%) 0.016
  White 79.5 88
  Black 17 8
  Hispanic 3.6 4
Center (%) <0.001
  Baltimore 30.8 26.7
  Chicago 25.9 14.7
  Pittsburgh 18.3 16.4
  UCLA 25 42.2
Smoking Status (%) 0.002
  Current 29.9 18.7
  Past 49.1 47.1
  Never 21 34.2
BMI (%) 0.400
  <20 kg/m2 4.5 3.1
  20 – 24.9 kg/m2 46.9 40.9
  25 – 29.9 kg/m2 35.3 38.7
  ≥ 30 kg/m2 13.4 17.3
HCV infection (%) 11.6 0.9 <0.001
History of diabetes (%) 8 5.3 0.252
Morning blood draw (%) 62.5 66.7 0.356
Free testosterone (FT, ng/dL) 66.1(52.4–81.5) 70.3(58.5–87.3) 0.011
Number of FT measurements contributed 4(3–5) 4(3–5) 0.331
Years from first FT to last FT measurements 5.5(2.9–9.4) 7.5(3–9.5) 0.155
HIV-positive (%) n 77.7 (n=174) 3.6 (n=8) <0.001
  Nadir CD4 count (cells/mm3) 223(149–336) 242(129–375) 0.806
  Current CD4 count (cells/mm3) 372(236–528) 307(235–589) 0.847
  HIV RNA < 400 copies/ml (%) 64.2 87.5 0.265
  Cumulative years on HAART 0.29(0.12–0.47) 0.35(0.19–0.49) 0.655
  History of AIDS (n) 16 1 0.753

Data are reported as median (interquartile range) or percentage.

*

By the non-parametric Wilcoxon test or Chi-square or Fisher exact test, as appropriate.